APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  2. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  3. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  4. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  5. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  6. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  7. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  8. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  9. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  10. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  11. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  12. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  13. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  14. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  15. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  16. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  17. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  18. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  19. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  20. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  21. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  22. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  23. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  24. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  25. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  26. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  27. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  28. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  29. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  30. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  31. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  32. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  33. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  34. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  35. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  36. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  37. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  38. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  39. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  40. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  41. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  42. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  43. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  44. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  45. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  46. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  47. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  48. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  49. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  50. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  51. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  52. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  53. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  54. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  55. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  56. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  57. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  58. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  59. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  60. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  61. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  62. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  63. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  64. Dong L, et al. 2021. Cancer Cell. . PubMed
  65. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  66. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  67. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  68. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  69. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  70. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  71. Solanki A, et al. 2018. Development. 145. PubMed
  72. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  73. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  74. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  75. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  76. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  77. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  78. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  79. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  80. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  81. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  82. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  83. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  84. Wang D, et al. 2018. Immunity. 48:659. PubMed
  85. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  86. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  87. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  88. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  89. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  90. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  91. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  92. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  93. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  94. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  95. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  96. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  97. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  98. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  99. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  100. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  101. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  102. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  103. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  104. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  105. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  106. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  107. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  108. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  109. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  110. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  111. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  112. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  113. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  114. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  115. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  116. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  117. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  118. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  119. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  120. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  121. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  122. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  123. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  124. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  125. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  126. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  127. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  128. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  129. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  130. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  131. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  132. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  133. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  134. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  135. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  136. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  137. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  138. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  139. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  140. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  141. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  142. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  143. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  144. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  145. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  146. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  147. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  148. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  149. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  150. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  151. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  152. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  153. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  154. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC, IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC-F, IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC, 3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC, IHC-F, 3D IHC, SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC, IHC, SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC, IP, Depletion, Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC, CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F, FC, 3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01-21-2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD8a

  • Biotin anti-mouse CD8a

  • FITC anti-mouse CD8a

  • PE anti-mouse CD8a

  • PE/Cyanine5 anti-mouse CD8a

  • Purified anti-mouse CD8a

  • PE/Cyanine7 anti-mouse CD8a

  • APC/Cyanine7 anti-mouse CD8a

  • Alexa Fluor® 488 anti-mouse CD8a

  • Alexa Fluor® 647 anti-mouse CD8a

  • Pacific Blue™ anti-mouse CD8a

  • Alexa Fluor® 700 anti-mouse CD8a

  • PerCP/Cyanine5.5 anti-mouse CD8a

  • PerCP anti-mouse CD8a

  • Brilliant Violet 421™ anti-mouse CD8a

  • Brilliant Violet 570™ anti-mouse CD8a

  • Brilliant Violet 650™ anti-mouse CD8a

  • Brilliant Violet 605™ anti-mouse CD8a

  • Ultra-LEAF™ Purified anti-mouse CD8a

  • Brilliant Violet 711™ anti-mouse CD8a

  • Brilliant Violet 785™ anti-mouse CD8a

  • Brilliant Violet 510™ anti-mouse CD8a

  • Purified anti-mouse CD8a (Maxpar® Ready)

  • Alexa Fluor® 594 anti-mouse CD8a

  • PE/Dazzle™ 594 anti-mouse CD8a

  • APC/Fire™ 750 anti-mouse CD8a

  • GoInVivo™ Purified anti-mouse CD8a

  • TotalSeq™-A0002 anti-mouse CD8a

  • Spark Blue™ 550 anti-mouse CD8a

  • Spark NIR™ 685 anti-mouse CD8a

  • TotalSeq™-C0002 anti-mouse CD8a

  • TotalSeq™-B0002 anti-mouse CD8a

  • Spark YG™ 570 anti-mouse CD8a

  • PE/Fire™ 640 anti-mouse CD8a

  • PE/Fire™ 700 anti-mouse CD8a

  • Spark Blue™ 574 anti-mouse CD8a Antibody

  • Spark Violet™ 423 anti-mouse CD8a Antibody

  • Spark UV™ 387 anti-mouse CD8a

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account